Healthcare stocks are usually filed under defensive investments: people need medicines and treatment in any economy. But the sector also has its own rhythms, driven by drug patents, product pipelines, regulation and the periodic rotation of investors into and out of safety. We measured the multi-year cycles of 26 long-history healthcare stocks and compared them with the Health Care Select Sector SPDR fund (XLV) and with SPY.
- XLV is one of the few sector funds with a measurable cycle: a slow 7.8-year wave with about a 4% chance of luck.
- Amgen, Bristol-Myers Squibb, CVS Health, Johnson & Johnson and Vertex show multi-year cycles of 4.5–7.6 years.
- Healthcare protected investors in crashes: XLV fell 37% in 2007–09 against SPY’s 52% and 14% in 2022 against 25%.
- But the sector has drawdowns of its own: from August 2024 to July 2025 XLV fell 17% while SPY rose 12%.
- The deepest single-stock declines were pipeline and patent stories: Bristol-Myers Squibb fell 49% in 2022–24 while XLV was flat and SPY rose 29%.
Why healthcare stocks move in cycles
Two forces overlap. The first is defensive rotation: like consumer staples, healthcare gains favour when growth slows and loses it in speculative bull markets. The second is the product cycle of drug makers and biotechnology companies: a blockbuster drug drives years of earnings growth, then patent expiration brings generic competition, and the stock waits for the next generation of products. Policy debates over drug pricing and insurance add sector-wide swings every few years.
Five healthcare stocks against XLV and SPY
The chart shows each stock’s swings around its own long-term trend; switch XLV and SPY on and off in the legend.
| Symbol | Name | Complete years | Strongest cycle | Chance it's luck | Cycle rating | Swing around trend | Typical peak spacing | Declines during S&P sell-offs | Moves with XLV | Moves with SPY |
|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | Amgen Inc | 42 | 4.5 yrs | 2% | Moderate | ±24% | 3.9 yrs | 3 of 7 | 0.37 | 0.37 |
| BMY | Bristol-Myers Squibb Company | 53 | 7.6 yrs | 2% | Moderate | ±12% | 3.5 yrs | 9 of 13 | 0.40 | 0.57 |
| CVS | CVS Health Corporation | 53 | 7.3 yrs | 2% | Moderate | ±18% | 2.3 yrs | 10 of 19 | 0.54 | 0.58 |
| JNJ | Johnson & Johnson | 56 | 4.9 yrs | 4% | Moderate | ±9% | 2.9 yrs | 9 of 15 | 0.42 | 0.35 |
| VRTX | Vertex Pharmaceuticals Inc | 34 | 4.6 yrs | 5% | Moderate | ±27% | 1.1 yrs | 7 of 14 | 0.22 | 0.31 |
| LLY | Eli Lilly and Company | 53 | 8.0 yrs | 12% | Weak | ±10% | 4.0 yrs | 8 of 10 | 0.46 | 0.45 |
| MRK | Merck & Co Inc | 53 | 5.3 yrs | 17% | None | ±10% | 3.4 yrs | 8 of 13 | 0.44 | 0.44 |
| PFE | Pfizer Inc | 53 | 7.2 yrs | 28% | None | ±9% | 2.7 yrs | 10 of 16 | 0.51 | 0.54 |
| UNH | UnitedHealth Group Inc | 41 | 5.2 yrs | 19% | None | ±18% | 1.8 yrs | 5 of 11 | 0.50 | 0.18 |
| ABT | Abbott Laboratories | 53 | 5.4 yrs | 31% | None | ±7% | 3.3 yrs | 8 of 15 | 0.36 | 0.42 |
| GILD | Gilead Sciences Inc | 33 | 5.9 yrs | 11% | Weak | ±15% | 1.5 yrs | 6 of 11 | 0.47 | 0.20 |
Biotechnology names have the largest swings: Amgen ±24% and Vertex ±27% around trend, with correlations to XLV of only 0.37 and 0.22, because their fortunes depend on individual drugs. The large pharmaceutical companies and insurers sit in between: Bristol-Myers Squibb (7.6 years, ±12%), CVS Health (7.3 years, ±18%) and Johnson & Johnson (4.9 years, ±9%). Eli Lilly, Merck and Pfizer show no reliable period.
Spotlight: XLV, the healthcare sector cycle
The healthcare sector fund has a slow, fairly regular cycle: peaks a median 2.8 years apart on shorter swings, riding a 7.8-year wave of about ±6% around trend. Its turning points are more regularly spaced than most funds’.
Lining up XLV’s drawdowns with SPY shows both sides of a defensive sector. In market-wide sell-offs (2002, 2007–09, 2011, 2020, 2022) healthcare usually fell less than the S&P 500. But its own corrections, in 2010, 2015 and especially 2024–25, came while the broad market was flat or rising.
| Peak – trough | Months | XLV | SPY same months | XLV recovery to next peak | During S&P sell-off |
|---|---|---|---|---|---|
| Aug 2024 – Jul 2025 | 11 | −17% | +12% | +45% (so far) | Yes |
| Dec 2021 – Sep 2022 | 9 | −14% | −25% | +30% | Yes |
| Dec 2019 – Mar 2020 | 3 | −13% | −20% | +59% | Yes |
| Jul 2015 – Sep 2015 | 2 | −14% | −9% | +54% | No |
| May 2011 – Sep 2011 | 4 | −12% | −16% | +141% | Yes |
| Mar 2010 – Aug 2010 | 5 | −13% | −10% | +29% | No |
| May 2007 – Feb 2009 | 21 | −37% | −52% | +40% | Yes |
| May 2002 – Sep 2002 | 4 | −15% | −24% | +45% | Yes |
Bristol-Myers Squibb and Amgen: product cycles
Bristol-Myers Squibb has a 7.6-year cycle and a history of long, company-specific drawdowns. It lost 70% from December 2000 to March 2003 while XLV slipped only 2%, and 49% from November 2022 to May 2024 while XLV gained 3% and SPY 29%, as investors weighed the patent expirations of its largest drugs. Amgen shows the same pattern: a 48% fall in 2005–08 while XLV and SPY were roughly flat, followed by a gain of more than 1,000% to its latest peak.
| Peak – trough | Months | BMY | XLV same months | SPY same months | BMY recovery to next peak | During S&P sell-off |
|---|---|---|---|---|---|---|
| Mar 2025 – Jul 2025 | 4 | −29% | −11% | +13% | +46% (so far) | Yes |
| Nov 2022 – May 2024 | 18 | −49% | +3% | +29% | +48% | Yes |
| Jul 2021 – Nov 2021 | 4 | −21% | −2% | +4% | +50% | Yes |
| Feb 2018 – Jul 2019 | 17 | −33% | +8% | +9% | +53% | Yes |
| Jul 2016 – Jan 2017 | 6 | −34% | −6% | +5% | +35% | No |
| Jun 2007 – Feb 2009 | 20 | −42% | −35% | −51% | +306% | Yes |
| Dec 2003 – Oct 2005 | 22 | −26% | +1% | +8% | +49% | No |
| Dec 2000 – Mar 2003 | 27 | −70% | −2% | −35% | +35% | Yes |
| Peak – trough | Months | AMGN | XLV same months | SPY same months | AMGN recovery to next peak | During S&P sell-off |
|---|---|---|---|---|---|---|
| Nov 2005 – Mar 2008 | 28 | −48% | +1% | +5% | +1,015% (so far) | Yes |
| Aug 2000 – Sep 2002 | 25 | −45% | −16% | −46% | +94% | Yes |
| May 1997 – Sep 1997 | 4 | −28% | – | +11% | +533% | No |
| Nov 1992 – Jul 1993 | 8 | −54% | – | – | +282% | No |
| May 1987 – Nov 1987 | 6 | −48% | – | – | +2,080% | Yes |
What this means for investors
- The sector fund is defensive; single stocks are not. XLV’s drawdowns have mostly been 12–17%, while individual drug makers have halved on product news.
- Healthcare has its own corrections, often driven by policy and pricing debates, that can occur while the market rises (as in 2024–25).
- Patent and pipeline cycles matter more than the business cycle for pharmaceutical and biotechnology stocks.
- Long waves. At about 7–8 years, the sector’s cycle requires patience.
How we measure a cycle: each symbol’s monthly closes are compared with their own long-term trend (a 10-year local regression of the log price). We then test every cycle length from 2 to 8 years and ask how often random price wandering with the same persistence produces a cycle at least as strong (120 simulations per symbol; this is the “chance it’s luck” column). Turning points are peaks and troughs separated by a reversal scaled to each symbol’s volatility. Prices exclude dividends. Full method in our guide to stock market cycles.
Frequently asked questions
As a sector, yes: XLV fell 37% in 2007–09 against SPY’s 52% and 14% in 2022 against 25%. Individual pharmaceutical and biotechnology stocks are much less defensive, because their prices depend on specific drugs, patents and trial results.
The healthcare sector fund XLV shows a slow 7.8-year cycle with about a 4% chance of luck, one of the few sector funds with a measurable cycle. Amgen, Bristol-Myers Squibb, CVS Health, Johnson & Johnson and Vertex show cycles of 4.5–7.6 years.
Mostly because of product cycles: when a blockbuster drug approaches patent expiration, investors price in falling sales until new drugs replace it. Bristol-Myers Squibb fell 49% in 2022–24 while SPY rose 29%. Drug-pricing policy debates can also hit the whole sector.
The Health Care Select Sector SPDR Fund (XLV) holds the healthcare companies in the S&P 500, including drug makers, medical-device companies, insurers and biotechnology firms. It is the benchmark we compare against here; this is not a recommendation.
Generally yes. In our data Amgen swings about ±24% and Vertex about ±27% around their long-term trends, compared with about ±9–12% for Johnson & Johnson and Bristol-Myers Squibb.
More market-cycle research
- Stock market cycles: what 55 years of data show
- Cyclical stocks: industrials and the 3.5-year business cycle
- Gold mining stocks: boom-and-bust cycles vs GDX, gold and the S&P 500
- Defensive stocks have cycles too: consumer staples
- Semiconductor stocks and the chip cycle
- Oil stocks and the oil price cycle
- Auto stocks and the car cycle: Ford, GM, Toyota and Tesla
- Tech stocks and market cycles: XLK and the Nasdaq
- Which stocks follow the S&P 500’s seasonal pattern?
Figures are historical, based on monthly closing prices to mid-November 2026, and are updated as new data arrives. Past cycles do not predict future returns; this is research, not investment advice.
